Detailansicht

Wissensnetz

Person

Martin Gramatzki

Arzt

Name	Martin Gramatzki
Ort	Kiel (Wirkungsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf) Hochschullehrer
Variante	M. Gramatzki
Beziehung	Medizinische Klinik und Poliklinik 2 (Kiel)
Weitere Angaben	Diss. Hannover 1978, Habil.-Schr. Erlangen-Nürnberg 1988; stellv. Direktor der Medizinischen Klinik II mit den Schwerpunkten Hämatologie und Onkologie, Leiter der Sektion für Stammzell- und Immuntherapie
Quelle	Kürschner Gelehrte (online, 2011)
Datensatztyp	Person
GND-Nummer	144039818
Datensatz-ID	144039818
Beteiligt an alle anzeigen Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display Alemtuzumab in der Therapie der akuten Graft-versus-Host-Erkrankung nach allogener Stammzelltransplantation Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network DuoFab-scFv als neuartiges Antikörperformat in der Therapie von B-Zell-Erkrankungen Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) Cardiovascular adverse events in modern myeloma therapy – incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma : : what to use and when From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT Ixazomib : innovativer Bestandteil einer oral verfügbaren Triplett-Therapie für Patienten mit rezidiviertem/refraktärem Multiplen Myelom Elotuzumab beim Multiplen Myelom : gezielte Immunaktivierung durch SLAMF7-Antikörper Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy Successful Mobilization, Intra-Apheresis Recruitment, and Harvest of Hematopoietic Progenitor Cells by Addition of Plerixafor and Subsequent Large-Volume Leukapheresis Immunologische Charakterisierung von Leukämien und Lymphomen : monoklonale Antikörper und Interleukin-2 The comparison of different rosette assay systems for the determination of T-Lymphocytes in patients with solid malignancies

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martin Gramatzki

Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

Alemtuzumab in der Therapie der akuten Graft-versus-Host-Erkrankung nach allogener Stammzelltransplantation

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

DuoFab-scFv als neuartiges Antikörperformat in der Therapie von B-Zell-Erkrankungen

Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Cardiovascular adverse events in modern myeloma therapy – incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma : : what to use and when

From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

Ixazomib : innovativer Bestandteil einer oral verfügbaren Triplett-Therapie für Patienten mit rezidiviertem/refraktärem Multiplen Myelom

Elotuzumab beim Multiplen Myelom : gezielte Immunaktivierung durch SLAMF7-Antikörper

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy

Successful Mobilization, Intra-Apheresis Recruitment, and Harvest of Hematopoietic Progenitor Cells by Addition of Plerixafor and Subsequent Large-Volume Leukapheresis

Immunologische Charakterisierung von Leukämien und Lymphomen : monoklonale Antikörper und Interleukin-2

The comparison of different rosette assay systems for the determination of T-Lymphocytes in patients with solid malignancies